23andMe, a popular direct-to-consumer genetic testing company, made headlines after its CEO pledged to help reunite the more than 2,300 children separated from their parents at the U.S.’s southern ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

23andMe, which sold saliva collection kits to consumers wanting insight into their genetic background, filed for bankruptcy in March 2025. The company has now agreed to sell its data bank to Regeneron ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

Capping off a dire run of bad news in the last year, 23andMe announced this week that it will be acquired by the pharmaceutical company, Regeneron. While this turn of events might not be the ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

23andMe was once a high-flying biotech firm. It collected a trove of DNA data on millions of its customers, and then it went bust. The fate of that data has been at the center of a legal battle over ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

New York and other states filed a lawsuit seeking to block 23andMe, the bankrupt genetic testing firm, from selling millions of Americans' genetic data to the highest bidder. A total of 28 state ...

Genetic testing company 23andMe laid off 100 employees on Jan. 23 due to decreasing sales of its direct-to-consumer DNA test kits, CNBC reports. The layoffs, which affect about 14 percent of the ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...